<unk>  is a live, attenuated Herpes Simplex Virus Type 1 that is FDA approved for the treatment of local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with  melanoma recurrent after initial surgery.<unk>  has not been shown to improve overall survival or have an effect on visceral metastases..   Common adverse reactions include fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain.
Talimogene laherparepvec
Interferon alfa-2a
Interferon alfa-2b
Interferon Alfa-n3
Pegylated interferon alfa-2a
Aldesleukin
Pegylated interferon alfa-2b
Idarucizumab